General Information of Drug (ID: DM24LNB)

Drug Name
YVAD Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9847365
TTD Drug ID
DM24LNB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Caspase-1 (CASP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AC-201 DMB0TNL Type-2 diabetes 5A11 Phase 2 [2]
Belnacasan DM2Q50G Epilepsy 8A60-8A68 Phase 2 [3]
PRALNACASAN DM73UTG Rheumatoid arthritis FA20 Phase 2 [4]
Nivocasan DMUX8JZ Fibrosis GA14-GC01 Phase 2 [5]
Ac-YVAD-FMK DM7K256 Allergic contact dermatitis EK00 Patented [6]
Ac-YVAD-cmk DMA1RVN Allergic contact dermatitis EK00 Patented [6]
VE-16084 DMHG70W Rheumatoid arthritis FA20 Terminated [7]
L-709049 DMQZW6D N. A. N. A. Terminated [8]
SDZ-224-015 DMY1KE8 Rheumatoid arthritis FA20 Terminated [9]
M826 DM9NPE4 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Caspase-1 (CASP1) TTCQIBE CASP1_HUMAN Inhibitor [1]

References

1 Mice deficient in interleukin-1beta converting enzyme resist anorexia induced by central lipopolysaccharide. Am J Physiol. 1999 Nov;277(5 Pt 2):R1435-43.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydr... J Pharmacol Exp Ther. 2007 May;321(2):509-16.
4 Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46.
5 Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis. 2013 Dec;18(12):1481-91.
6 Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59.
7 Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine. 1996 May;8(5):377-86.
8 Succinic acid amides as P2-P3 replacements for inhibitors of interleukin-1beta converting enzyme (ICE or caspase 1). Bioorg Med Chem Lett. 2010 Sep 1;20(17):5184-90.
9 Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6.
10 Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.